Review on the coronavirus disease (COVID-19) pandemic: Its outbreak and current status

被引:45
作者
Almaghaslah, Dalia [1 ]
Kandasamy, Geetha [1 ]
Almanasef, Mona [1 ]
Vasudevan, Rajalakshimi [1 ]
Chandramohan, Sriram [2 ]
机构
[1] King Khalid Univ, Coll Pharm, Dept Clin Pharm, Alsamer Campus, Abha 61441, Saudi Arabia
[2] Saudi Elect Univ, Dept Publ Hlth, Riyadh, Saudi Arabia
关键词
2019-NCOV; VIRULENCE; MERS;
D O I
10.1111/ijcp.13637
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: In late December 2019 and on 1st January 2020, the coronavirus (COVID-19) infecting humans was first identified in Wuhan, Hubei Province, China. Later cases have also been confirmed worldwide. Coronaviruses are RNA viruses that are phenotypically and genotypically diverse. Globally, as of 6th April 2020, laboratory confirmed cases of COVID-19 reported to the World Health Organisation (WHO) amounted to 1 211 214, including 67 666 deaths. Aim: In the current study, we performed a literature review on coronavirus outbreak to summarise details about the pathogenesis, epidemiology, diagnosis and the management strategies for the disease control. Pathogenesis: Coronaviruses are tremendously precise and mature only in differentiated respiratory epithelial cells, as seen in both organ cultures as well as human volunteers. This virus will cause the antiviral T-cell response to be erratic, owing to the T-cell apoptosis activation, triggering the immune system to collapse. Transmission: The understanding of the transmission of COVID-19 risk is incomplete. The transmission mainly occurs through the respiratory droplets once an infected person sneezes, like the spread of flu and other respiratory infectious agents. Clinical presentation: Presentations of COVID-19 includes fever, cough, shortness of breath, malaise and respiratory distress. Treatment: There have been no approved vaccines available for COVID-19 until today. The Ministry of Science and Technology in the People's Republic of China declared three potential antiviral medicines suitable for treating COVID-19. Those three medicines are, namely, favilavir, chloroquine phosphate and remdesivir. Hydroxychloroquine combined with azithromycin enhances the reduction of the viral load in COVID-19 patients. Conclusion: The corona virus transmits quicker than its two predecessors the MERS-CoV and SARS-CoV, but has reduced casualty. The global effects of this latest pandemic are still unclear. Nevertheless, considering that so far no vaccine has been available; preventive approaches are the best way to fight against the virus.
引用
收藏
页数:9
相关论文
共 65 条
[1]  
AlNajjar N S, 2017, East Mediterr Health J, V22, P817
[2]  
American College of Obstetricians and Gynecologistsy, Practice advisory: novel coronavirus 2019 (COVID-19). e
[3]  
[Anonymous], COR DIS COVID 19 PAN
[4]  
[Anonymous], CLIN MAN SEV AC RES
[5]  
[Anonymous], 2020, Coronavirus Disease 2019
[6]   Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20-28 January 2020 [J].
Backer, Jantien A. ;
Klinkenberg, Don ;
Wallinga, Jacco .
EUROSURVEILLANCE, 2020, 25 (05) :10-15
[7]  
Bai S L, 2020, Zhonghua Yu Fang Yi Xue Za Zhi, V54, pE005, DOI 10.3760/cma.j.issn.0253-9624.2020.0005
[8]  
Cascella M., 2020, FEATURES EVALUATION
[9]  
*CDCP, COR DIS 2019 COVID 1
[10]  
Centers for Disease Control and Prevention, 2020, Interim Guidelines for COVID-19 Antibody Testing